PL1843754T3 - Nowa kompozycja farmaceutyczna zawierająca cyleksetyl kandesartanu jako lipofilową substancję krystaliczną - Google Patents

Nowa kompozycja farmaceutyczna zawierająca cyleksetyl kandesartanu jako lipofilową substancję krystaliczną

Info

Publication number
PL1843754T3
PL1843754T3 PL06700941T PL06700941T PL1843754T3 PL 1843754 T3 PL1843754 T3 PL 1843754T3 PL 06700941 T PL06700941 T PL 06700941T PL 06700941 T PL06700941 T PL 06700941T PL 1843754 T3 PL1843754 T3 PL 1843754T3
Authority
PL
Poland
Prior art keywords
pharmaceutical composition
composition containing
candesartan cilexetil
crystalline substance
new pharmaceutical
Prior art date
Application number
PL06700941T
Other languages
English (en)
Inventor
Zdenka Jerala-Strukelj
Igor Legen
Original Assignee
Lek Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceuticals filed Critical Lek Pharmaceuticals
Publication of PL1843754T3 publication Critical patent/PL1843754T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL06700941T 2005-01-26 2006-01-24 Nowa kompozycja farmaceutyczna zawierająca cyleksetyl kandesartanu jako lipofilową substancję krystaliczną PL1843754T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SI200500021 2005-01-26
PCT/EP2006/000587 WO2006079496A1 (en) 2005-01-26 2006-01-24 New pharmaceutical composition containing candesartan cilexetil as lipophilic crystalline substance
EP06700941A EP1843754B1 (en) 2005-01-26 2006-01-24 New pharmaceutical composition containing candesartan cilexetil as lipophilic crystalline substance

Publications (1)

Publication Number Publication Date
PL1843754T3 true PL1843754T3 (pl) 2011-12-30

Family

ID=36035685

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06700941T PL1843754T3 (pl) 2005-01-26 2006-01-24 Nowa kompozycja farmaceutyczna zawierająca cyleksetyl kandesartanu jako lipofilową substancję krystaliczną

Country Status (9)

Country Link
US (1) US20080118564A1 (pl)
EP (1) EP1843754B1 (pl)
JP (1) JP2008528456A (pl)
AT (1) ATE518526T1 (pl)
DK (1) DK1843754T3 (pl)
ES (1) ES2371145T3 (pl)
PL (1) PL1843754T3 (pl)
SI (1) SI1843754T1 (pl)
WO (1) WO2006079496A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007001065A2 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Method for the preparation of a wet granulated drug product
TWI494134B (zh) * 2006-06-20 2015-08-01 Siegfried Generics Int Ag 含有坎地沙坦酯的組成物、錠劑和顆粒及該錠劑的製造方法
WO2008045006A1 (en) * 2006-10-11 2008-04-17 Fako Ilaclari A. S. Formulations of candesartan
ES2301401B1 (es) * 2006-11-28 2009-06-08 Laboratorios Liconsa S.A. Composicion farmaceutica solida estabilizada de candesartan cilexetilo.
PT2165702E (pt) 2008-09-17 2012-02-07 Helm Ag Composições estáveis e rapidamente dissolvidas de candesartan cilexetil preparadas com granulação húmida
CN102415998A (zh) * 2010-09-28 2012-04-18 扬子江药业集团北京海燕药业有限公司 盐酸马尼地平固体分散体及其制备方法
JP2013224265A (ja) * 2012-04-19 2013-10-31 Asahi Kasei Chemicals Corp 打圧感受性薬物を含有する錠剤
WO2014088123A1 (en) 2012-12-05 2014-06-12 Sawai Pharmaceutical Co., Ltd. Candesartan cilexetil-containing preparation
CN103006598B (zh) * 2012-12-31 2015-12-02 广州白云山天心制药股份有限公司 含氯化钠药物载体的降血压片剂
ES2768651T3 (es) 2013-04-25 2020-06-23 Kyorin Seiyaku Kk Composición farmacéutica sólida
JP5844929B1 (ja) * 2015-04-03 2016-01-20 共和薬品工業株式会社 カンデサルタンシレキセチル及びヒドロクロロチアジドを含む錠剤
EP3219309A1 (en) * 2016-03-17 2017-09-20 K.H.S. Pharma Holding GmbH Fixed dosed pharmaceutical composition comprising amlodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension
CN110876726A (zh) * 2019-11-20 2020-03-13 白喜平 一种坎地沙坦酯制剂及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
TW284688B (pl) * 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
CN1215338A (zh) * 1996-04-05 1999-04-28 武田药品工业株式会社 包含具有血管紧张素ⅱ拮抗活性的化合物的药物组合物
US6210710B1 (en) * 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
EP1561458B1 (en) * 1998-07-28 2010-09-15 Takeda Pharmaceutical Company Limited Rapidly disintegrable solid preparation
RS50377B (sr) * 1999-08-30 2009-11-10 Sanofi-Aventis Deutschland Gmbh., Inhibitori sistema renin-angiotenzin i njihova primena
DE10029201A1 (de) * 2000-06-19 2001-12-20 Basf Ag Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung
WO2002030400A1 (fr) * 2000-10-06 2002-04-18 Takeda Chemical Industries, Ltd. Preparations solides
WO2003000169A1 (en) * 2001-06-20 2003-01-03 Takeda Chemical Industries, Ltd. Method of manufacturing tablet
AUPS236902A0 (en) * 2002-05-16 2002-06-13 Northern Sydney Area Health Service Composition and method for treating hypertension
US20040202730A1 (en) * 2003-04-08 2004-10-14 Robert Gow Rosmarinic acid composition

Also Published As

Publication number Publication date
SI1843754T1 (sl) 2011-12-30
WO2006079496A1 (en) 2006-08-03
ES2371145T3 (es) 2011-12-27
EP1843754A1 (en) 2007-10-17
JP2008528456A (ja) 2008-07-31
US20080118564A1 (en) 2008-05-22
ATE518526T1 (de) 2011-08-15
EP1843754B1 (en) 2011-08-03
DK1843754T3 (da) 2011-11-21

Similar Documents

Publication Publication Date Title
SI1843754T1 (sl) Novi farmacevtski sestavek, ki vsebuje kandesartan cileksetil kot lipofilno kristalinično snov
MY151468A (en) Controlled release solid preparation
AR068369A1 (es) Sal de xinafoato de n4-[(2,2-difluor-4h-benzo[1,4]oxazin-3-on)-6-il]-5-fluor-n2-[3-(metilaminocarbonilmetilenoxi)-fenil]2,4-pirimidindiamina"
MY151295A (en) Pyrimidyl indoline compound
EA201001852A1 (ru) Твердые фармацевтические составы, содержащие bibw 2992
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
MX2011012627A (es) Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
TW200626158A (en) Naphthaline derivatives
PE20060771A1 (es) Profarmaco de amida de gemcitabina y composiciones que lo contienen
UA109421C2 (uk) Фармацевтична композиція, яка містить ліганди сигма-рецептора
WO2009082152A3 (en) Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient
MY151470A (en) Controlled release solid preparation
NO20043367L (no) Oralt farmasoytisk preparat
UA110013C2 (uk) Застосування композиції для лікування шарко-марі-тута і пов'язаних з нею розладів
JO2973B1 (en) Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol
WO2009060952A1 (ja) 新規製剤
MY163762A (en) Therapeutic agent for chronic renal failure
CL2009001267A1 (es) Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis.
TW200626581A (en) Compounds, compositions containing them, preparation thereof and uses thereof
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent
EP1584335A3 (en) Active substance combination comprising a carbinol composition and an opioid
AR056369A1 (es) Compuestos derivados de quinazolina y composicion farmaceutica
TW200531693A (en) Prolonged-release diuretic compositions
EP1852119A4 (en) PHARMACEUTICAL PREPARATION CONTAINING PHENOXAZINIUM DERIVATIVE AS ACTIVE INGREDIENT